Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNIOR STRENGTH MOTRIN vs JUNIOR STRENGTH ADVIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
FDA-approved for relief of mild to moderate pain,fever reduction,off-label uses include migraine and dysmenorrhea
FDA-labeled: Temporary relief of minor aches and pains (e.g., headache, toothache, menstrual cramps, muscle aches, backache),Fever reduction,Off-label: Osteoarthritis, rheumatoid arthritis (in higher doses),Off-label: Patent ductus arteriosus closure in neonates
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
Primarily hepatic via CYP2C9, with minor contributions from CYP2C8 and glucuronidation.
Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
99% bound to albumin.
90-99% bound to albumin; concentration-dependent.
0.2 L/kg in children; low Vd indicates limited tissue distribution and high plasma protein binding. Clinical: mainly confined to vascular compartment.
0.1-0.2 L/kg (low, consistent with high protein binding).
Oral: 80-100% (rapid absorption); rectal: approximately 70-80%.
Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules).
GFR 30-59 m L/min: reduce dose by 50% or avoid; GFR <30 m L/min: contraindicated.
e GFR 30-60 m L/min: reduce dose by 50% or extend interval to q8-12h; e GFR <30 m L/min: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use.
6 months to 12 years: 5-10 mg/kg per dose orally every 6-8 hours; maximum 40 mg/kg/day.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months.
Initiate at lowest effective dose; consider renal function; increase dosing interval to every 6-8 hours.
Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
Risk of GI ulceration, bleeding, and perforation; increased cardiovascular thrombotic events; hypertension; fluid retention and edema; severe skin reactions (e.g., Stevens-Johnson syndrome); renal toxicity, especially in patients with impaired renal function; anaphylactoid reactions.
Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke,Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation,Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease,Hypersensitivity reactions: Anaphylaxis, bronchospasm,Fluid retention and edema,Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus)
Hypersensitivity to ibuprofen or any NSAID; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; history of GI bleeding or perforation related to NSAIDs.
Hypersensitivity to ibuprofen or any component of the formulation,Asthma, urticaria, or allergic-type reactions after aspirin or other NSAID use,Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery,Use in children with chickenpox (due to increased risk of severe skin reactions)
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol while taking this medication as it increases risk of stomach bleeding.
Avoid alcohol: increases risk of GI bleeding. Limit caffeine as may increase side effects. Can be taken with food or milk to minimize GI irritation.
First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second trimester: Generally considered lower risk, but avoid prolonged use. Third trimester: Known association with premature closure of the ductus arteriosus, oligohydramnios, and fetal renal dysfunction; contraindicated after 30 weeks gestation.
Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01-0.02). Peak milk concentration occurs 1-2 hours after maternal dose. Due to the low concentration and short half-life in infants, ibuprofen is considered compatible with breastfeeding when used at recommended doses for short durations.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Not expected to cause adverse effects in infants with short-term use at recommended doses. Avoid in nursing mothers breastfeeding preterm or low-birth-weight infants.
No specific dose adjustment is recommended in pregnancy for occasional use. However, due to pharmacokinetic changes (increased volume of distribution and clearance), lower doses may be less effective; use the lowest effective dose for the shortest duration. Avoid routine use after 20 weeks due to fetal risks.
No specific dose adjustment recommended in pregnancy. However, use lowest effective dose for shortest duration. In third trimester, avoid use unless benefit outweighs risk of fetal toxicity.
For pediatric patients, use weight-based dosing (5-10 mg/kg/dose) rather than age-based to ensure efficacy and safety. Limit to 4 doses per day; maximum 40 mg/kg/day or 1.2 g/day, whichever is less. Do not combine with other NSAIDs. Use lowest effective dose for shortest duration. Contraindicated in children with active peptic ulcer disease, severe renal impairment, or known hypersensitivity to ibuprofen or aspirin.
For pediatric patients, weight-based dosing is critical; typical dose is 5-10 mg/kg/dose every 6-8 hours. Avoid use in children with dehydration, bleeding disorders, or aspirin allergy. May mask signs of infection. Not recommended for children under 6 months.
Give with food or milk to reduce stomach upset.,Use weight-based dosing: shake suspension well before use; use dosing syringe or cup provided.,Do not exceed 4 doses in 24 hours; wait at least 4 hours between doses.,Do not give with other pain relievers containing ibuprofen, naproxen, or aspirin.,Stop use and consult doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Seek medical help immediately if signs of allergic reaction (rash, hives, swelling, trouble breathing) or stomach bleeding (bloody or black stools, vomit that looks like coffee grounds) occur.
Give with food or milk to reduce stomach upset.,Do not exceed recommended dose; overdose can cause liver damage or gastrointestinal bleeding.,Do not use with other products containing ibuprofen or NSAIDs.,Shake suspension well before measuring dose using appropriate dosing device.,Stop use and consult doctor if symptoms worsen or new symptoms occur.,Keep out of reach of children; in case of overdose, contact Poison Control immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNIOR STRENGTH MOTRIN vs JUNIOR STRENGTH ADVIL, answered by our medical review team.
JUNIOR STRENGTH MOTRIN is a NSAID Analgesic that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. JUNIOR STRENGTH ADVIL is a NSAID Analgesic that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNIOR STRENGTH MOTRIN and JUNIOR STRENGTH ADVIL depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNIOR STRENGTH MOTRIN is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. The standard adult dose of JUNIOR STRENGTH ADVIL is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNIOR STRENGTH MOTRIN and JUNIOR STRENGTH ADVIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNIOR STRENGTH MOTRIN is classified as Category C. First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second t. JUNIOR STRENGTH ADVIL is classified as Category C. Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.